Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2005

View Archived Issues

A novel EphA2-targeting antibody conjugated to MMAF reverses tumor growth

Takeda offers six-month development update

Enrollment complete in study of ETHOS I stent

Anti-TNF-alpha vaccine works in arthritic mice

Fractalkine identified as a novel target for the treatment of atherosclerosis

Obestatin: a newly identified hormone that suppresses appetite

Neose Technologies receives milestone payment from Novo Nordisk

Acambis begins pivotal program for ChimeriVax-JE

Preliminary results from phase I study of IPL-455903

Sinovac cleared to advance pandemic influenza vaccine into Chinese clinical testing

Wex preparing IND for Tectin

First patient dosed in phase II study of VRX-496 for HIV

FDA approves updated labeling for Lexiva

Research objective met in Arius and Protein Design Labs' collaboration

CF-101 demonstrates efficacy in phase II rheumatoid arthritis trial

Liposome entrapped c-raf antisense oligonucleotide assessed in phase I study

Flurizan taken beyond 1 year improved cognition in Alzheimer's disease patients

D3 antagonists may provide a useful adjunct to levodopa therapy

T-817MA improves beta-amyloid-induced learning deficits in rats

Shire submits BLA for Elaprase for Hunter's syndrome

GlaxoSmithKline seeks Japanese approval for fondaparinux sodium

Theravance prepares and tests 5-HT4 receptor agonists for gastrointestinal disorders

Recent patents disclose novel agents for the treatment of endocrine-related disorders

Belimumab activity, safety revealed in phase II rheumatoid arthritis trial

Animal studies support clinical evaluation of TACI-Ig

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...